Ontology highlight
ABSTRACT: Objective
This study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials.Study design
Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice.Results
Twenty-one (81%) clinical trial rings had contraceptive hormone levels within the range of those used as a contraceptive choice. Five returned rings had unused or discordant levels of residual contraceptive hormones.Conclusion
Residual vaginal ring drug levels could help assess adherence in clinical trials.
SUBMITTER: Haaland RE
PROVIDER: S-EPMC5551387 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
Haaland Richard E RE Holder Angela A Evans-Strickfaden Tammy T Nyagol Beatrice B Makanga Mumbi M Oyaro Boaz B Humwa Felix F Williams Tiffany T McLellan-Lemal Eleanor E Desai Mitesh M Huey Michael J MJ
Contraception 20170401 6
<h4>Objective</h4>This study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials.<h4>Study design</h4>Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice.<h4>Results</h4>Twenty-one (81%) clinical trial rings ha ...[more]